- Home
- KRRO vs ATOS Comparison
KRRO vs ATOS Comparison
Compare KRRO & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRRO
- ATOS
- Stock Information
- Founded
- KRRO 2014
- ATOS 2009
- Country
- KRRO United States
- ATOS United States
- Employees
- KRRO N/A
- ATOS N/A
- Industry
- KRRO Biotechnology: Pharmaceutical Preparations
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- KRRO Health Care
- ATOS Health Care
- Exchange
- KRRO Nasdaq
- ATOS Nasdaq
- Market Cap
- KRRO 101.4M
- ATOS 112.5M
- IPO Year
- KRRO 2019
- ATOS 2012
- Fundamental
- Price
- KRRO $12.35
- ATOS $0.79
- Analyst Decision
- KRRO Strong Buy
- ATOS Strong Buy
- Analyst Count
- KRRO 7
- ATOS 3
- Target Price
- KRRO $85.67
- ATOS $6.17
- AVG Volume (30 Days)
- KRRO 200.2K
- ATOS 648.7K
- Earning Date
- KRRO 08-12-2025
- ATOS 08-11-2025
- Dividend Yield
- KRRO N/A
- ATOS N/A
- EPS Growth
- KRRO N/A
- ATOS N/A
- EPS
- KRRO N/A
- ATOS N/A
- Revenue
- KRRO $4,821,000.00
- ATOS N/A
- Revenue This Year
- KRRO $65.08
- ATOS N/A
- Revenue Next Year
- KRRO N/A
- ATOS N/A
- P/E Ratio
- KRRO N/A
- ATOS N/A
- Revenue Growth
- KRRO N/A
- ATOS N/A
- 52 Week Low
- KRRO $10.29
- ATOS $0.55
- 52 Week High
- KRRO $98.00
- ATOS $1.66
- Technical
- Relative Strength Index (RSI)
- KRRO 41.55
- ATOS 44.68
- Support Level
- KRRO $11.50
- ATOS $0.80
- Resistance Level
- KRRO $16.86
- ATOS $0.86
- Average True Range (ATR)
- KRRO 1.50
- ATOS 0.05
- MACD
- KRRO 0.01
- ATOS -0.01
- Stochastic Oscillator
- KRRO 31.35
- ATOS 17.33
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.